BeOne Medicines (ONC) Interest Coverage Ratio (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Interest Coverage Ratio of 7.6 for Q1 2026, up 787.12% year-over-year from 0.86 in Q1 2025, and down 15.5% quarter-over-quarter from 8.99 in Q4 2025.
BeOne Medicines (ONC) Interest Coverage Ratio (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Interest Coverage Ratio for 12 consecutive years, with 7.6 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 787.12% year-over-year to 7.6; the TTM figure through Mar 2026 stood at 8.78 (up 267.84% YoY), while the FY2025 annual figure was 0.12, up 173.42% from the prior year.
- Interest Coverage Ratio slipped to 7.6 in Q1 2026 per ONC's latest filing, from 8.99 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 12.89 in Q3 2025 and bottomed at 80.54 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 28.18 across 5 years, with a median of 20.21 in 2023.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio sank 763.55% — and 2026, when it surged 787.12%.
- BeOne Medicines' Interest Coverage Ratio stood at 57.16 in 2022, then surged by 44.47% to 31.74 in 2023, then jumped by 84.41% to 4.95 in 2024, then soared by 281.8% to 8.99 in 2025, then retreated by 15.5% to 7.6 in 2026.
- Business Quant data shows ONC's Interest Coverage Ratio at 7.6 in Q1 2026, 8.99 in Q4 2025, and 12.89 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.18 |
| Mar 31, 2026 | 7.60 |
| Dec 31, 2025 | 8.99 |
| Sep 30, 2025 | 12.89 |
| Jun 30, 2025 | 7.29 |
| Mar 31, 2025 | 0.86 |
| Dec 31, 2024 | -4.95 |
| Sep 30, 2024 | -8.40 |
| Jun 30, 2024 | -8.10 |
| Mar 31, 2024 | -21.07 |
| Dec 31, 2023 | -31.74 |
| Sep 30, 2023 | -20.21 |
| Jun 30, 2023 | -65.16 |
| Mar 31, 2023 | -74.00 |
| Dec 31, 2022 | -57.16 |
| Sep 30, 2022 | -78.33 |
| Jun 30, 2022 | -80.54 |
| Mar 31, 2022 | -66.99 |
| Dec 31, 2021 | 26.93 |
| Sep 30, 2021 | -60.76 |